AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- Robert Wasserman, director of Research for Dawson James Securities, a division of ViewTrade Financial, has initiated coverage on Immune Response Corporation (IMNR) with a buy rating and a 12-month price target of $8-$10.
Dawson James is a research-oriented healthcare/biotech boutique investment firm with offices in Florida and New Jersey.
IMNR, based in Carlsbad, California, is developing a therapeutic vaccine for the treatment of human immunodeficiency virus (HIV) infection. Currently, IMNR is focusing its research and development efforts on Remune, an immune-based therapy for HIV infection which was been the subject of ...
Source: HighBeam Research, Dawson James Securities initiates coverage of HIV vaccine developer.